Saloranta 2002

1 Treatments

Studied treatment nateglinide (30, 60, or 120 mg, with meals).

Control treatment placebo

Concomittant treatments -

2 Patients

Patients patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter)

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding double-blind

Design Parallel groups

Centers multicenter

Geographical area -

Sizes 675/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References